Orally administered Mycobacterium vaccae modulates expression of immunoregulatory molecules in BALB/c mice with pulmonary tuberculosis

Clinical and Vaccine Immunology

Volumn 15, Issue 11, 2008, Pages 1730-1736

  Hernández Pando, Rogelio ^a   Aguilar, Diana ^a   Orozco, Hector ^a   Cortez, Yuriria ^a   Brunet, Laura Rosa ^b   Rook, Graham A ^c  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b Centre Point   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEME OXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 4; INTERLEUKIN 4DELTA2; MYCOBACTERIUM VACCINE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; LUNG TUBERCULOSIS; MALE; MOUSE; MYCOBACTERIUM VACCAE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; COLONY COUNT, MICROBIAL; CYTOKINES; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; LUNG; MALE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 55849132619     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00286-08     Document Type: Article

References (36)

1. Adams, V. C., J. R. Hunt, R. Martinelli, R. Palmer, G. A. Rook, and L. R. Brunet. 2004. Mycobacterium vaccae induces a population of pulmonary CD11c+ cells with regulatory potential in allergic mice. Eur. J. Immunol. 34:631-638.
2. Centers for Disease Control and Prevention. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb. Mortal. Wkly. Rep. 55:301-305.
3. Chattopadhyay, S., and N. G. Chakraborty. 2005. Continuous presence of Th1 conditions is necessary for longer lasting tumor-specific CTL activity in stimulation cultures with PBL. Hum. Immunol. 66:884-891.
4. Churchyard, D. J. 2007. Report of the expert consultation on immunotherapeutic interventions for tuberculosis. TDR/World Health Organization, Geneva, Switzerland.
5. Demissie, A., M. Abebe, A. Aseffa, G. Rook, H. Fletcher, A. Zumla, K. Weldingh, I. Brock, P. Andersen, T. M. Doherty, and the VACSEL Study Group. 2004. Healthy individuals that control a latent infection with M. tuberculosis express high levels of Th-1 cytokines and the IL-4 antagonist IL-4δ2. J. Immunol. 172:6938-6943.
6. Dlugovitzky, D., G. Fiorenza, M. Farroni, C. Bogue, C. Stanford, and J. Stanford. 2006. Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis. Respir. Med. 100:1079-1087.
7. Fletcher, H. A., P. Owiafe, D. Jeffries, P. Hill, G. A. W. Rook, A. Zumla, T. M. Doherty, R. Brookes, and the VACSEL Study Group. 2004. Increased expression of mRNA encoding IL-4 and its splice variant IL-4δ2 in cells from contacts of Mycobacterium tuberculosis in the absence of in vitro stimulation. Immunology 112:669-673.
8. Grohmann, U., F. Fallarino, and P. Puccetti. 2003. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24:242-248.
9. Harris, J., S. A. De Haro, S. S. Master, J. Keane, E. A. Roberts, M. Delgado, and V. Deretic. 2007. T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. Immunity 27:505-517.
10. Hernandez-Pando, R., D. Aguilar, M. L. Garcia Hernandez, H. Orozco, and G. A. W. Rook. 2004. Pulmonary tuberculosis in Balb/c mice with nonfunctional IL-4 genes; changes in the inflammatory effects of TNF-a and in the regulation of fibrosis. Eur. J. Immunol. 34:174-183.
11. Hernandez-Pando, R., H. Orozco, A. Sampieri, L. Pavón, C. Velasquillo, J. Larriva-Sahd, J. M. Alcocer, and M. V. Madrid. 1996. Correlation between the kinetics of Th1/Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology 89:26-33.
12. Hernandez-Pando, R., H. Orozco-Esteves, H. A. Maldonado, D. Aguilar-Leon, M. M. Vilchis-Landeros, D. A. Mata-Espinosa, V. Mendoza, and F. Lopez-Casillas. 2006. A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis. Clin. Exp. Immunol. 144:264-272.
13. Hernandez-Pando, R., L. Pavön, K. Arriaga, H. Orozco, V. Madrid-Marina, and G. Rook. 1997. Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte. Infect. Immun. 65:3317-3327.
14. Hernandez-Pando, R., L. Pavon, E. H. Orozco, J. Rangel, and G. A. W. Rook. 2000. Interactions between hormone-mediated and vaccine-mediated immunotherapy for pulmonary tuberculosis in Balb/c mice. Immunology 100:391-398.
15. Hill, M., S. Tanguy-Royer, P. Royer, C. Chauveau, K. Asghar, L. Tesson, F. Lavainne, S. Remy, R. Brion, F. X. Hubert, M. Heslan, M. Rimbert, L. Berthelot, J. R. Moffett, R. Josien, M. Gregoire, and I. Anegon. 2007. IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur. J. Immunol. 37:3054-3062.
16. Hunt, J. R., R. Martinelli, V. C. Adams, G. A. W. Rook, and L. Rosa Brunet. 2005. Intragastric administration of Mycobacterium vaccae inhibits severe pulmonary allergic inflammation in a mouse model. Clin. Exp. Allergy 35:685-690.
17. Khazaie, K., and H. von Boehmer. 2006. The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin. Cancer Biol. 16:124-136.
18. Kursar, M., M. Koch, H. W. Mittrucker, G. Nouailles, K. Bonhagen, T. Kamradt, and S. H. Kaufmann. 2007. Cutting edge: regulatory T cells prevent efficient clearance of Mycobacterium tuberculosis. J. Immunol. 178:2661-2665.
19. Lee, S. S., W. Gao, S. Mazzola, M. N. Thomas, E. Csizmadia, L. E. Otterbein, F. H. Bach, and H. Wang. 2007. Heme oxygenase-1, carbon monoxide, and bilirubin induce tolerance in recipients toward islet allografts by modulating T regulatory cells. FASEB J. 21:3450-3457.
20. Morse, D., and A. M. Choi. 2002. Heme oxygenase-1: the "emerging molecule" has arrived. Am. J. Respir. Cell Mol. Biol. 27:8-16.
21. Ricklin-Gutzwiller, M. E., M. Reist, J. E. Peel, W. Seewald, L. R. Brunet, and P. J. Roosje. 2007. Intradermal injection of heat-killed Mycobacterium vaccae in dogs with atopic dermatitis: a multicentre pilot study. Vet. Dermatol. 18:87-93.
22. Rook, G., K. Dheda, and A. Zumla. 2005. Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting? Vaccine 23:2115-2120.
23. Rook, G. A. 2007. Th2 cytokines in susceptibility to tuberculosis. Curr. Mol. Med. 7:327-337.
24. Rook, G. A. W., and R. Hernandez-Pando. 1996. The pathogenesis of tuberculosis. Annu. Rev. Microbiol. 50:259-284.
25. Rook, G. A. W., R. Hernandez-Pando, and A. Zumla. Tuberculosis due to high-dose challenge in partially immune individuals: a problem for vaccination? J. Infect. Dis., in press.
26. Roy, E., J. Brennan, S. Jolles, and D. B. Lowrie. 2007. Beneficial effect of anti-interleukin-4 antibody when administered in a murine model of tuberculosis infection. Tuberculosis 88:197-202.
27. Siawaya, J. F. D., N. B. Bapela, K. Ronacher, N. Beyers, P. van Helden, and G. Walzl. 2008. Differential expression of interleukin-4 (IL-4) and IL-4δ2, but not transforming growth factor beta (TGF-β), TGF-βRII, Foxp3, gamma interferon, T-bet, or GATA-3 mRNA, in patients with fast and slow re-sponses to antituberculosis treatment. Clin. Vaccine Immunol. 15:1165-1170.
28. + cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis. Infect. Immun. 65:4525-4530.
29. Stewart, G. R., M. Boussinesq, T. Coulson, L. Elson, T. Nutman, and J. E. Bradley. 1999. Onchocerciasis modulates the immune response to mycobacterial antigens. Clin. Exp. Immunol. 117:517-523.
30. Vasiliev, A. M., R. N. Vasilenko, N. L. Kulikova, S. M. Andreev, I. O. Chikileva, G. Y. Puchkova, I. V. Kosarev, A. V. Khodyakova, V. S. Khlebnikov, L. R. Ptitsyn, G. Y. Shcherbakov, V. N. Uversky, L. M. DuBuske, and V. M. Abramov. 2003. Structural and functional properties of IL-4delta2, an alternative splice variant of human IL-4. J. Proteome Res. 2:273-281.
31. Wassie, L., A. Demissie, A. Aseffa, M. Abebe, L. Yamuah, H. Tilahun, B. Petros, G. A. W. Rook, A. Zumla, A. Andersen, T. M. Doherty, and the VACSIS Study Group. 2008. Ex vivo cytokine mRNA levels correlate with changing clinical status of Ethiopian TB patients and their contacts over time. PLoS ONE 3:e1522.
32. Wu, H. P., C. L. Wu, C. C. Yu, Y. C. Liu, and D. Y. Chuang. 2007. Efficiency of interleukin-4 expression in patients with tuberculosis and nontubercular pneumonia. Hum. Immunol. 68:832-838.
33. Xia, Z. W., L. Q. Xu, W. W. Zhong, J. J. Wei, N. L. Li, J. Shao, Y. Z. Li, S. C. Yu, and Z. L. Zhang. 2007. Heme oxygenase-1 attenuates ovalbumin-induced airway inflammation by up-regulation of foxp3 T-regulatory cells, interleukin-10, and membrane-bound transforming growth factor-beta1. Am. J. Pathol. 171:1904-1914.
34. Yatsenko, O. P., M. L. Filipenko, E. N. Voronina, E. A. Khrapov, S. V. Sennikov, and V. A. Kozlov. 2004. Alternative splicing of murine interleukin-4 mRNA. Bull. Exp. Biol. Med. 137:179-181.
35. Zuany-Amorim, C., C. Manlius, A. Trifilieff, L. R. Brunet, G. Rook, G. Bowen, G. Pay, and C. Walker. 2002. Long-term protective and antigen-specific effect of heat-killed Mycobacterium vaccae in a murine model of allergic pulmonary inflammation. J. Immunol. 169:1492.
36. Zuany-Amorim, C., E. Sawicka, C. Manlius, A. Le Moine, L. R. Brunet, D. M. Kemeny, G. Bowen, G. Rook, and C. Walker. 2002. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat. Med. 8:625-629.